Tracon Pharmaceuticals, Inc.
Tracon Pharmaceuticals, Inc. (TCON): 3 pipeline candidates · ~7 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.9 months
0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Tracon Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$6.3M
Quarterly Burn
$2.8M
Runway
6.9 mo
Revenue
$55K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| envafolimab | Phase 2 |
| trc102 | Phase 2 |
| yh001 | Phase 1 |
Frequently asked questions
How many drug candidates are in Tracon Pharmaceuticals, Inc.'s pipeline?
Tracon Pharmaceuticals, Inc. (TCON) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Tracon Pharmaceuticals, Inc.'s lead drug candidate?
Tracon Pharmaceuticals, Inc.'s most advanced tracked candidate is envafolimab (Phase 2) for sarcoma (specifically undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS)).
What is Tracon Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Tracon Pharmaceuticals, Inc. has approximately 6.9 months of cash runway.
Who is the CEO of Tracon Pharmaceuticals, Inc.?
Craig Jalbert Craig is the chief executive officer of Tracon Pharmaceuticals, Inc. (TCON).
Get the full picture on Tracon Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.